RE: Posts28 Jun 2021 00:03
Hi Threeskins. I'm largely in agreement with you, my initial shares in Premaitha came from my involvement in Vialogy and I first purchased directly in '14 and I have topped up every now and then since. My attraction to the company was the NIPT product that was top quality with not a lot of competition so capable of achieving a good margin. The subsequent acquisition of Elucigene maintained my view.
When we developed the Clarigen test this board was awash with posts re this. However my view was that the Covid test was counter to the point above. My thinking was that because every body and their dog was also developing tests it was clear to me that the high amount of competition would erode margins and long term was not the our core business was being developed.
Don't get me wrong, I think it was advantageous in that it promoted the company and demonstrated our nimbleness and ability to adapt to current events and develop a gold standard product. The sales will be most welcome, albeit at lower margins, and will prop up the year end figures and give us time help us to recover and develop our core business. As an example the recent US deal is timed to come on stream at the start of our next financial year and so be a long term and hopefully incremental revenue line. I hope the market appreciates this and that we are capable of this type of long term niche products that we are able to develop, and improve, with little competition. I'm certain this where the long term profits lie.